A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Recently, mutations in the connection subdomain (CN) and RNase H domain of HIV-1 reverse transcriptase (RT) were observed to exhibit dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). To elucidate the mechanism by which CN and RH mutations confer resistance to NNRTIs, we hypothesized that these mutations reduce RNase H cleavage and provide more time for the NNRTI to dissociate from the RT, resulting in the resumption of DNA synthesis and enhanced NNRTI resistance. We observed that the effect of the reduction in RNase H cleavage on NNRTI resistance is dependent upon the affinity of each NNRTI to the RT and further influenced by the presence of NNRTI-binding pocket (BP) mutants. D549N, Q475A, and Y501A mutants, which reduce RNase H cleavage, enhance resistance to nevirapine (NVP) and delavirdine (DLV), but not to efavirenz (EFV) and etravirine (ETR), consistent with their increase in affinity for RT. Combining the D549N mutant with NNRTI BP mutants further increases NNRTI resistance from 3- to 30-fold, supporting the role of NNRTI-RT affinity in our NNRTI resistance model. We also demonstrated that CNs from treatment-experienced patients, previously reported to enhance NRTI resistance, also reduce RNase H cleavage and enhance NNRTI resistance in the context of the patient RT pol domain or a wild-type pol domain. Together, these results confirm key predictions of our NNRTI resistance model and provide support for a unifying mechanism by which CN and RH mutations can exhibit dual NRTI and NNRTI resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, this approach is supported by the observation that a single substitution mutation in RT significantly lowers the dimerization affinity, suggesting that it is possible to reduce dimerization by targeting key contacts in the interface [107,118-121].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [107]
Citations
Cites
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., & Arnold, E. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.071 · Cited by 535
Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors
Spence, R. A., Kati, W. M., Anderson, K. S., & Johnson, K. A. (1995) · Science · doi:10.1126/science.7532321 · Cited by 522
Das, K., Clark, Lewi, P. J., Heeres, J., de Jonge, M. R., Koymans, L. M. H., Vinkers, H. M., Daeyaert, F., Ludovici, D. W., Kukla, M. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030558s · Cited by 514
Yee, J. K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C., & Friedmann, T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9564 · Cited by 487
Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4680-4686.2004 · Cited by 322
Vingerhoets, J., Azijn, H., Fransen, E., De Baere, I., Smeulders, L., Jochmans, D., Andries, K., Pauwels, R., & de Béthune, M.-P. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12773-12782.2005 · Cited by 249
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
Hsiou, Y., Ding, J., Das, K., Clark, A. D., Boyer, P. L., Lewi, P., Janssen, P. A. J., Kleim, J.-P., Rösner, M., Hughes, S. H., et al. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4648 · Cited by 195
Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., & Stuart, D. I. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3984 · Cited by 195
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
Sluis-Cremer, N., & Tachedjian, G. (2008) · Virus Research · doi:10.1016/j.virusres.2008.01.002 · Cited by 172
Research works printed but not linked: 3
- Nikolenko, G. N., K. A. Delviks-Frankenberry, A. Jere, and V. K. Pathak. 2008. Mutations in the reverse transcriptase connection and RNase H domains exhibit dual resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors. Antivir. Ther.13:A55-A55.
- Sharma, S. K., N. Fan, K. B. Rank, L. A. Kopta, R. A. Olmsted, S. M. Poppe, D. E. Slade, R. C. Thomas, and W. G. Tarpley. 1995. A drug-resistance mutation (G190E) in the inhibitor binding pocket impairs both RNA-dependent DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. J. Acquir. Immune Defic. Syndr. Hum. Retrovir.10:2.
- 10.1021/bi952058 · doi:10.1021/bi952058
Cited by
de Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Esposito, F., Corona, A., & Tramontano, E. (2012) · Molecular Biology International · doi:10.1155/2012/586401 · Cited by 138
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor
Luca, L. D., Ferro, S., Gitto, R., Barreca, M. L., Agnello, S., Christ, F., Debyser, Z., & Chimirri, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.051 · Cited by 65
Menéndez‐Arias, L., Betancor, G., & Matamoros, T. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.08.020 · Cited by 51
The “Connection” Between HIV Drug Resistance and RNase H
Delviks‐Frankenberry, K. A., Nikolenko, G. N., & Pathak, V. K. (2010) · Viruses · doi:10.3390/v2071476 · Cited by 48
Self-citation
Metadata
- Authors
- Nikolenko, G. N., Delviks-Frankenberry, K. A., & Pathak, V. K.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, Maryland 21702
- Corresponding author
- Pathak, Vinay K.
- ORCID
- Pathak, Vinay K.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2010-05-15
- Volume
- 84
- Issue
- 10
- Pages
- 5238-5249
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2863829
- OpenAlex
- W2018143554
- Cited by
- 47
- References
- 58
- Citations by year
- 2026: 1 · 2025: 1 · 2021: 3 · 2020: 1 · 2017: 3 · 2016: 1 · 2015: 6 · 2014: 3 · 2013: 7 · 2012: 6
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010532)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- HIV-1 reverse transcriptase, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, RNase H cleavage, nevirapine, delavirdine, efavirenz, etravirine, drug binding affinity, treatment-experienced patients
- MeSH terms
- Humans, HIV-1, Ribonuclease H, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Mutation, Missense, Drug Resistance, Viral, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. https://app.cochat.ai/papers/10.1128/jvi.01545-09
- The paper
- Nikolenko, G. N., Delviks-Frankenberry, K. A., & Pathak, V. K. (2010). A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Virology. https://doi.org/10.1128/jvi.01545-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.